Pembrolizumab (Keytruda®) for neoadjuvant/adjuvant treatment of triple negative breast cancer. HTA ID: 22027

Assessment Status Full HTA submission received from Applicant
HTA ID 22027
Drug Pembrolizumab
Brand Keytruda®
Indication Is indicated in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.
Assessment Process
Rapid review commissioned 27/04/2022
Rapid review completed 26/05/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard-of-care.
Full pharmacoeconomic assessment commissioned by HSE 01/07/2022
Pre-submission consultation with Applicant 30/08/2022
Full submission received from Applicant 16/03/2023